[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hereditary-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hereditary-cancer":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,51,82,146],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100637829","expanding-genetic-access-for-prostate-cancer-survivors-100637829",false,"NCT07618520","Expanding Genetic Access for Prostate Cancer Survivors","Expanding Genetic Access and Guided Education for Prostate Cancer Survivors","ENGAGE","Inclusion Criteria:\n\n* 18-80 years of age\n* At least 6-months post diagnosis with prostate cancer\n* Have not had genetic testing for hereditary cancer\n* Have received care at one of the participating sites in the prior five years\n* Meet National Comprehensive Cancer Network criteria for germline GT\n* Able to read and speak in English\n* Capable of providing informed consent\n* Have internet access (via smartphone, tablet or computer)\n* Comfortable using a computer or mobile phone independently to access information\n\nExclusion Criteria:\n\n* Do not speak English\n* Unable to access the Internet\n* Have previously undergone germline genetic testing for hereditary cancer risk or previously had genetic counseling (GC) and declined genetic testing (GT)\n* Are unable to provide informed consent","MALE","18 Years","80 Years",{"count":21,"type":22},500,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this study is to increase genetic education and genetic testing for hereditary cancer risk among prostate cancer survivors. The study will:\n\nTest the effectiveness of a digital guide (DG+) vs. print guide (Print+) vs. enhanced usual care (EUC) on engagement in genetic education and uptake of genetic testing.\n\nEvaluate the impact of the DG+ vs. Print+ vs. EUC on the process that participants use to make decisions and evaluate effects on well-being (also called psychosocial outcomes).\n\nExplore the ways (methods) that influence how participants experience the intervention.\n\nThe main questions this study aims to answer are: which group - the digital guide (DG+) group, print (Print+) group or the EUC group - is more likely to request genetic testing and which group is more likely to get (engage with) genetic education.\n\nParticipants will be randomly assigned to either the digital guide (DG+) group, the print guide (Print+) group or EUC group. Each group will receive genetic education and have an opportunity to request genetic testing. Researchers will compare the three groups to determine which is most most likely to complete genetic testing (GT) and which group engages more with genetic education.",[28,29,30],"Prostate Cancer Patients","Hereditary Cancer","Genetic Testing",[32,33,34,35,36,37],"Prostate cancer","survivorship","genetic counseling","genetic testing","hereditary cancer","Chatbot","NOT_YET_RECRUITING","2026-05-25",{"date":41,"type":42},"2026-06-01","ACTUAL",{"date":44,"type":22},"2026-08-01",{"date":46,"type":22},"2030-07-31",{"name":48,"class":49},"Georgetown University","OTHER",2,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":58,"minAge":18,"maxAge":4,"enrollmentInfo":59,"targetDuration":61,"studyType":62,"phases":4,"briefSummary":63,"conditions":64,"keywords":69,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":81},"100584924","ucsf-biobank-for-hereditary-cancers-and-tumor-associated-mutations-100584924","NCT06895681","UCSF Biobank for Hereditary Cancers and Tumor-Associated Mutations","UCSF Biobank for Studying Hereditary Cancers and Tumor-Associated Mutations","Inclusion Criteria:\n\nFor participants undergoing collection of tissue, ascites, and\u002For pleural effusions:\n\n1. Ability to understand and willingness to voluntarily sign a written informed consent document prior to any study-related assessments or procedures are conducted.\n2. Individuals 18 years of age or older on the day of signing informed consent.\n3. Individuals with solid tumor malignancy with germline or somatic cancer-associated mutations and\u002For Individuals with a family history or personal history of cancer.\n4. Must be planning to undergo one of the following procedures as part of their routine care (or as a research procedure under a UCSF-sponsored IIT protocol):\n\n   1. Surgical resection\n   2. Biopsy (open, incisional, excisional, punch, core needle, and\u002For fine needle aspiration (FNA) are all permitted)\n   3. Paracentesis\n   4. Thoracentesis\n\nFor participants undergoing blood banking:\n\n1. Ability to understand and willingness to voluntarily sign a written informed consent document prior to any study-related assessments or procedures are conducted.\n2. Individuals 18 years of age or older on the day of signing informed consent.\n3. Individuals with a family history or personal history of cancer.\n4. Must be planning to undergo a blood draw as part of their routine care (or as a research procedure under a University of California, San Francisco (UCSF) -sponsored investigator-initiated trial (IIT) protocol); or willing to undergo an additional blood draw outside of their routine care.\n\nExclusion Criteria:\n\n1\\. Known history of HIV, Hepatitis B, or Hepatitis C (as documented in the medical record) or other infectious disease that in the judgment of the investigator could pose a risk to research personnel or mice, or negatively impact Patient derived xenografts (PDX) tumor engraftment.","ALL",{"count":60,"type":22},50000,"10 Years","OBSERVATIONAL","This is a non-therapeutic clinical research biorepository protocol designed to obtain, store, and clinically annotate biospecimens from participants with hereditary cancers. Those biospecimens will be used to generate participant-derived tumor models that will serve as a resource to better understand hereditary cancers and develop new efficient therapies.",[65,66,67,68,29],"Solid Tumor","Solid Tumor, Adult","Somatic Mutation","Solid Tumor, Unspecified, Adult",[70,71],"Germline Mutations","Tumor-Associated Mutations","2026-04-28",{"date":74,"type":42},"2026-05-04",{"date":76,"type":22},"2026-08-31",{"date":78,"type":22},"2035-12-31",{"name":80,"class":49},"University of California, San Francisco",1,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":58,"minAge":18,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":92,"conditions":93,"keywords":115,"overallStatus":135,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":145},"100570529","lynch-syndrome-x-talk-of-enteral-mucosa-with-immune-system-100570529","NCT06708429","Lynch Syndrome X-Talk of Enteral Mucosa With Immune System","Impact of Immune-surveillance on the Development of Colorectal Cancer in Patients With Lynch Syndrome","LYNX-EYE","Inclusion Criteria (for participants with Lynch syndrome):\n\n* Age ≥18 years\n* All sexes eligible\n* Established diagnosis of Lynch syndrome performed as part of clinical practice, with a germline pathogenic\u002Flikely pathogenic variant in one of the following genes: MLH1, MSH2, MSH6, PMS2, and EpCAM\n* Subjects with Lynch syndrome undergoing surveillance gastrointestinal endoscopy and\u002For surgery according to clinical practice\n* Fertile patients (both males and females) are eligible\n* Lactating women are eligible\n\nInclusion Criteria (for participants without Lynch syndrome):\n\n* Age ≥18 years\n* All sexes eligible\n* Patients with sporadic colorectal lesions, including colorectal cancer and colorectal adenomas\n* Healthy controls without colorectal cancer or adenomas undergoing lower gastrointestinal endoscopy for abdominal pain\n* PREMM5 \\\u003C 2.5 \\[PREMM5 is an online, free-to-use, clinical prediction algorithm that estimates the cumulative probability of an individual carrying a germline mutation in the mismatch repair genes responsible for Lynch syndrome\\].\n\nExclusion Criteria (for participants with or without Lynch syndrome):\n\n* Age \\\u003C 18 years;\n* Diseases that are known to predispose to colorectal cancer (personal past or recent history of inflammatory bowel disease);\n* Patients unable\u002Funwilling to provide consent;\n* Pregnancy",{"count":91,"type":22},300,"Lynch syndrome (OMIM #120435) is the most common dominantly inherited colorectal cancer syndrome with an estimated prevalence of 1:270 individuals. It increases the lifetime risk of colorectal and endometrial cancer primarily, but it is associated with a high risk of other cancers (pancreas, stomach, ovarian, central nervous system, skin, among others). It is caused by a germline mutation in one of four DNA mismatch repair genes or a terminal deletion of the MSH2-adjacent gene EpCAM.\n\nDespite adherence to cancer surveillance programs, many patients still develop colorectal cancer and endometrial cancer. The Prospective Lynch Syndrome Database (PLSD) suggests that more frequent surveillance intervals do not significantly improve cancer risk reduction. The PLSD also revealed that the incidence of colorectal cancer in MLH1 and MSH2 carriers was even higher than previously expected, reaching as high as 41-36% among MLH1 carriers, regardless of ethnic background. The development of colorectal cancer despite surveillance is an unresolved question. Therefore, there is an unmet need for effective cancer prevention strategies.",[94,95,96,97,98,99,100,29,101,102,103,104,105,106,107,108,109,110,111,112,113,114],"Lynch Syndrome","Lynch Syndrome I","Lynch Syndrome II","Lynch Syndrome I (Site-specific Colonic Cancer)","HNPCC","HNPCC Gene Mutation","Hereditary Cancer Syndrome","MLH1 Gene Mutation","MLH1 Gene Deletion+Duplication","MLH1 Loss of Expression","MLH1 Gene Inactivation","MSH2 Gene Mutation","MSH2 Gene Deletion+Duplication","MSH2 Loss of Expression","MSH2 Gene Inactivation","MSH6 Gene Mutation","MSH6 Loss of Expression","MSH6 Gene Inactivation","PMS2 Gene Mutation","PMS2 Gene Inactivation","PMS2 Loss of Expression",[116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134],"Colorectal cancer","Endometrial cancer","Lynch syndrome-associated cancer","Surveillance","Cancer surveillance","Immune profile","Immune escape","Mismatch repair deficiency","Microbiota","Liquid biopsy","MicroRNA","Transcriptomic","Frame shift peptides","MLH1","MSH2","EpCAM","MSH6","PMS2","Hair matrix","RECRUITING","2026-04-21",{"date":138,"type":42},"2026-04-24",{"date":140,"type":42},"2023-06-01",{"date":142,"type":22},"2034-06-01",{"name":144,"class":49},"San Raffaele University",5,{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":152,"sex":58,"minAge":18,"maxAge":19,"enrollmentInfo":153,"targetDuration":4,"studyType":23,"phases":155,"briefSummary":156,"conditions":157,"keywords":158,"overallStatus":135,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":50},"100521748","addressing-genomic-disparities-in-cancer-survivors-100521748","NCT06073626","Addressing Genomic Disparities in Cancer Survivors","Inclusion Criteria:\n\n* 18-80 years of age\n* Self-identify as Black or African American\n* At least 6-months post diagnosis with any of the following cancers: breast, ovarian, uterine, prostate, colorectal, pancreatic\n* Have not had genetic testing for hereditary cancer\n* Have received care at one of the participating sites in the prior five years\n* Meet National Comprehensive Cancer Network criteria for germline GT\n* Able to read and speak in English\n* Capable of providing informed consent\n* Have internet access (via smartphone, tablet or computer)\n* Comfortable using a computer or mobile phone independently to access information\n\nExclusion Criteria:\n\n* Do not speak English\n* Unable to access the Internet\n* Have previously undergone germline genetic testing for hereditary cancer risk or previously had genetic counseling (GC) and declined genetic testing (GT)\n* Are unable to provide informed consent",true,{"count":154,"type":22},428,[25],"The goal of this observational study is to increase genetic education and genetic testing for hereditary cancer risk among Black cancer survivors. The study will:\n\n1. Test the effectiveness of a chatbot intervention (also called relational agent, or RA) vs. enhanced usual care (EUC) on engagement in genetic education and requests for genetic testing.\n2. Evaluate the impact of the chatbot vs. EUC on the process that participants use to make decisions and evaluate effects on well-being (also called psychosocial outcomes).\n3. Explore the ways (methods) that influence how participants experience the intervention.\n4. Explore the feasibility of incorporating a Family Sharing Portal (FSP) for participants who receive a positive test result, to facilitate family communication of these test results and genetic testing of first-degree biological relatives after they have received genetic education by the RA.\n\nThe main questions this study aims to answer are which group - the chatbot (RA) group or the EUC group - is more likely to request genetic testing and which group is more likely to get (engage with) genetic education.\n\nParticipants will be randomly assigned to either the chatbot (RA) group or EUC group. This means each participant has an equal chance of being placed in either group, just like flipping a coin. Each group will receive genetic education and have an opportunity to request genetic testing. Researchers will compare the chatbot (RA) group and the EUC group to see which may request more GT (genetic testing) and which group engages more with genetic education.",[29,30],[36,35,159,160,161],"genetic education","relational agent","chatbot","2025-10-24",{"date":164,"type":42},"2025-10-28",{"date":166,"type":42},"2024-07-31",{"date":168,"type":22},"2027-08-31",{"name":170,"class":49},"Rutgers, The State University of New Jersey"]